Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6

A new experimental NS5A inhibitor, GS-5816, was shown to be safe and effective when used in an interferon- and ribavirin-free dual regimen with sofosbuvir (Sovaldi) for people

Published
17 April 2014
By
Liz Highleyman
NHS England agrees funding for life-saving hepatitis C drug

NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C. Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.

Published
17 April 2014
From
NHS England (press release)
England: Patients with end-stage liver disease caused by hepatitis C to get new drug

The NHS is to pay for around 500 people with end-stage liver disease caused by hepatitis C to receive Sofosbuvir, a new drug which could cure them, without waiting for guidance from the advisory body, Nice.

Published
17 April 2014
From
The Guardian
BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks

A combination of two direct-acting antivirals developed by Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without

Published
17 April 2014
By
Keith Alcorn
Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease

Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and

Published
16 April 2014
By
Liz Highleyman
AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis

The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to

Published
15 April 2014
By
Keith Alcorn
AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C

A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode

Published
14 April 2014
By
Keith Alcorn
Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients

A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the

Published
14 April 2014
By
Liz Highleyman
Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis

A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or ribavirin led to sustained virological response in 93% of people with genotype

Published
14 April 2014
By
Liz Highleyman
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible,

Published
11 April 2014
By
Keith Alcorn
← First12345...93Next →

Filter by country